Oncology and Hematology - MedEd On The Go

Episodes 33-48 of 69

Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME/CE
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
0.50 credits
- Justin Gainor, MD
- Jacob Sands, MD
0.50 credits
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
MinuteCE®
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
MinuteCE®
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
1.00 program credit
- John Mascarenhas, MD
- Gabriela Hobbs, MD
1.00 program credit
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
MinuteCE®
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Real-World Experience With Pacritinib in the US
Real-World Experience With Pacritinib in the US
MinuteCE®
Real-World Experience With Pacritinib in the US
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Managing Myelofibrosis-Associated Thrombocytopenia
Managing Myelofibrosis-Associated Thrombocytopenia
MinuteCE®
Managing Myelofibrosis-Associated Thrombocytopenia
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
Managing Myelofibrosis-Associated Anemia
Managing Myelofibrosis-Associated Anemia
MinuteCE®
Managing Myelofibrosis-Associated Anemia
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
MinuteCE®
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
MinuteCE®
Tailoring JAK Inhibitor Therapy in Patients With Myelofibrosis
1.00 credit 10 episodes
- John Mascarenhas, MD
- Gabriela Hobbs, MD
1.00 credit 10 episodes
Improving Transfusion Independence With JAK Inhibitor Therapy
Improving Transfusion Independence With JAK Inhibitor Therapy
MinuteCE®
Improving Transfusion Independence With JAK Inhibitor Therapy
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
MinuteCE®
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
How and When to Manage Ruxolitinib Failure
How and When to Manage Ruxolitinib Failure
MinuteCE®
How and When to Manage Ruxolitinib Failure
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Current Unmet Needs in the Field of Unresectable HCC
Current Unmet Needs in the Field of Unresectable HCC
MinuteCE®
Current Unmet Needs in the Field of Unresectable HCC
1.00 program credit
- Ghassan K. Abou-Alfa, MD
- Aiwu Ruth He, MD, PhD
1.00 program credit
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
MinuteCE®
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
1.00 program credit
- Ghassan K. Abou-Alfa, MD
- Aiwu Ruth He, MD, PhD
1.00 program credit

3/5